Getting Real with RWE
By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…
CertaraNovember 20, 2020
SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
CertaraOctober 20, 2020
Payment Pressures in U.S. Specialty: Status quo and outlook for future financing
To allow for the optimal positioning of your product, portfolio, or company, it is critical…
CertaraSeptember 15, 2020
The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
CertaraFebruary 19, 2020
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
CertaraDecember 19, 2019
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
CertaraOctober 24, 2019
Innovative Solutions for Fast-Tracking Drugs for Rare Diseases
This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…
CertaraAugust 10, 2019
Evidence and Access Overview
Discover Certara’s holistic approach to market access.
CertaraMay 21, 2019
